A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti–PD-1 mAb, in patients with advanced or metastatic solid tumors

A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti–PD-1 mAb, in patients with advanced or metastatic solid tumors

BackgroundQL1604 is a humanized immunoglobulin G4 monoclonal antibody against programmed cell death protein 1. This first-in-human, open-label phase I study aimed to investigate the safety and tolerability and to identify the recommended doses of QL1604 for future studies. Pharmacokinetics/pharmacod...

Full description

Bibliographic Details
Main Authors: Zhiyu Huang, Yanjun Xu, Wei Hong, Lei Gong, Kaiyan Chen, Jing Qin, Fajun Xie, Feng Wang, Xin Tian, Xiangrui Meng, Wenlei Feng, Lingyan Li, Baihui Zhang, Xiaoyan Kang, Yun Fan
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Immunology
Subjects:
QL1604
anti-PD-1 mAb
advanced solid tumors
tolerability
first-in-human
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1258573/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1258573/full

Similar Items